Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized study of CNTO328 plus VELCADE-melphalan-prednisone versus VELCADE-melphalan-prednisone in previously untreated multiple myeloma
2008-007157-12Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of siltuximab in multiple myeloma (MM) (2 arms), sponsored by Janssen Biotech. Primary endpoints: Safety (Part 1) and Complete response rate (Part 2). Started Mar 2009; status: completed.
02
Drugs
siltuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-007157-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007157-12.